Ovid Therapeutics Inc.
OVID· Nasdaq
Released Mar 15, 2021, before the open
10-K filed Mar 15, 2021, 74 days after period end · 0001564590-21-013016
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Net Income | -$22.03M | -$16.97M | -$12.90M | -$10.96M |
| EPS Diluted | — | -$0.35 | -$0.52 | -$0.45 |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.